IFRX Stock Risk & Deep Value Analysis
InflaRx NV
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About IFRX Stock
We analyzed InflaRx NV using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran IFRX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
Get notified when IFRX moves
Same alert types as Telegram — presets or custom thresholds in your 🔔 feed.
📈IFRX Performance Overview3yr weekly
Unlock IFRX Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
IFRX Risk Analysis & Red Flags
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
Low
Upcoming Risk Events
- 📅
Failure to secure adequate or favorable financing terms, leading to severe dilution or insolvency
- 📅
Continued slow commercial uptake of Gohibic, missing sales targets
- 📅
Adverse clinical trial results for pipeline candidates or new indications
- 📅
Increased competitive pressure from new or existing treatments for ANCA-associated vasculitis
Unlock IFRX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does InflaRx NV (IFRX) Do?
Market Cap
$81.30M
Sector
Healthcare
Industry
Biotechnology
Employees
74
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Visit InflaRx NV WebsiteInvestment Thesis
InflaRx represents an extremely high-risk, high-reward investment focused on the successful commercialization of its EU-approved orphan drug, Gohibic, for ANCA-associated vasculitis. Despite a clear market opportunity and unique drug profile, the company faces immediate existential financial challenges due to a critically short cash runway and slow sales uptake. A successful, non-dilutive financing event coupled with dramatically accelerated sales are prerequisites for IFRX to survive and potentially achieve its 10x growth potential.
Is IFRX Stock Undervalued?
Unlock the full AI analysis for IFRX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
IFRX Price Targets & Strategy
12-Month Target
$2.50
Bull Case
$5.00
Bear Case
$0.10
Entry Strategy
Extremely high risk. Only suitable for aggressive investors with a high-risk tolerance. Consider a very small, speculative position via dollar-cost averaging on dips below $0.80, contingent on clear positive developments regarding financing or accelerated sales.
Exit Strategy
Take 50% profit at $2.50, re-evaluate at $5.00 for further upside. Implement a strict stop-loss order below $0.70 due to critical cash runway concerns and potential delisting risks.
Portfolio Allocation
1% for aggressive risk tolerance only
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Does IFRX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable but vulnerable
Moat Sources
1 Identified
The moat is primarily derived from intellectual property and regulatory exclusivity. Its durability hinges on successful commercialization, further clinical development, and maintaining differentiation against new competitive entrants or alternative therapies. If commercial execution fails, the regulatory and IP moat becomes less valuable.
Moat Erosion Risks
- •Failure to effectively commercialize Gohibic, leading to loss of potential market share
- •Emergence of superior, more convenient, or more cost-effective treatments for ANCA-associated vasculitis
- •Expiration of key patents or orphan drug status without significant market entrenchment
IFRX Competitive Moat Analysis
Sign up to see competitive advantages
IFRX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bearish
Institutional Sentiment
Negative
Insider Activity (Form 4)
No significant recent insider buying detected, indicating a lack of strong conviction from management at current levels.
Options Flow
Limited activity, no clear directional signals, reflecting a lack of significant institutional or retail options interest.
Earnings Intelligence
Next Earnings
Estimated early-May 2026 (for Q1 2026)
Surprise Probability
Low
Historical Earnings Pattern
Highly volatile reactions to earnings reports; tends to sell off on weak sales or increasing cash burn, but could see significant upside on positive financing news or substantial sales acceleration.
Key Metrics to Watch
Competitive Position
Top Competitor
AMGN (Amgen - via acquisition of ChemoCentryx's Tavneos (avacopan))
Market Share Trend
Losing/Stable (struggling to gain significant market share against established and emerging competitors in ANCA-associated vasculitis).
Valuation vs Peers
Trading at a significant discount to peers due to its early commercial stage, high cash burn, and financial uncertainty. Traditional valuation metrics are largely inapplicable.
Competitive Advantages
- •Unique mechanism of action (C5a inhibitor) for Gohibic
- •Orphan drug designation in the EU provides market exclusivity
- •Existing EU regulatory approval for a specific indication
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive IFRX Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated early-mid May 2026), focusing on Gohibic sales and cash position
- •Financing announcement (equity, debt, or partnership) - critical and imminent
- •Updates on Gohibic commercialization efforts and market penetration in the EU
Medium-Term (6-18 months)
- •Sustained acceleration in Gohibic sales and revenue growth in European markets
- •Potential strategic partnerships for global commercialization or additional indications
- •Progress on vilobelimab's development pipeline or expansion into new therapeutic areas
Long-Term (18+ months)
- •Establishment of Gohibic as a leading treatment for ANCA-associated vasculitis globally
- •Expansion of vilobelimab's approved indications, broadening the TAM
- •Potential acquisition by a larger pharmaceutical company seeking to enhance its rare disease portfolio
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for IFRX?
- ✓
Significant acceleration in Gohibic sales figures (quarter-over-quarter growth)
- ✓
Announcement of a favorable financing deal or strategic partnership that significantly extends the cash runway
- ✓
Positive clinical data for vilobelimab in new indications
- ✓
Failure to secure financing, continued slow sales, or highly dilutive equity offerings
Bull Case Analysis
Sign up free to see the bull case
Competing with IFRX
See how InflaRx NV compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
InflaRx NV IFRX | $81.3M | 4.0 | — | — | — | — | |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for InflaRx NV (IFRX)?
As of March 12, 2026, InflaRx NV has a DVR Score of 4.0 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of InflaRx NV?
InflaRx NV's market capitalization is approximately $81.3M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does InflaRx NV use?
IFRX is the ticker symbol for InflaRx NV. The company trades on the NMS.
What is the risk level for IFRX stock?
Our analysis rates InflaRx NV's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the IFRX DVR analysis updated?
Our AI-powered analysis of InflaRx NV is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 12, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for IFRX (InflaRx NV) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.